相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
Rajendra Badwe et al.
LANCET ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
D. A. Yardley et al.
BRITISH JOURNAL OF CANCER (2014)
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
F. Montemurro et al.
ANNALS OF ONCOLOGY (2013)
Meta-Analysis to Determine if Surgical Resection of the Primary Tumour in the Setting of Stage IV Breast Cancer Impacts on Survival
Elly Harris et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
Ji-Won Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factore-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
Ines Vaz-Luis et al.
CLINICAL BREAST CANCER (2013)
First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Debu Tripathy et al.
ONCOLOGIST (2013)
Clinicopathologic Characteristics and Prognostic Factors in Patients with Operable HER-2 Overexpressing Breast Cancer
Ai-Na Liu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
Olivia Pagani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Francisco J. Esteva et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
Rosa Giuliani et al.
EUROPEAN JOURNAL OF CANCER (2007)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
